The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN) - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evolving Approaches to Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis from the European Myeloma Network (EMN)

  • By

  • Heinz Ludwig

  • Evangelos Terpos

  • Francesca Gay

  • Niels W. C. J. van de Donk

  • Sarah Bernhard

  • Monika Engelhardt

  • Gordon Cook

  • Fredrik Schjesvold

  • Hermann Einsele

  • Graham Jackson

  • Charlotte Pawlyn

  • María-Victoria Mateos

  • Sonja Zweegman

  • Martin Schreder

  • Meral Beksaç

  • Christoph Driessen

  • Enrique M. Ocio

  • Rakesh Popat

  • Leo Rasche

  • Cyrille Touzeau

  • Pellegrino Musto

  • Annemiek Broijl

  • Meletios Dimopoulos

  • Roman Hajek

  • Mario Boccadoro

  • Pieter Sonneveld

  • June 18, 2026

Share

Clinical Scorecard: Evolving Approaches to Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis from the European Myeloma Network (EMN)

At a Glance

CategoryDetail
ConditionMultiple Myeloma
Key MechanismsMaintenance therapy aims to deepen responses, prolong remission, delay disease progression, and improve overall survival.
Target PopulationPatients with newly diagnosed multiple myeloma (NDMM), including those eligible and ineligible for transplantation.
Care SettingClinical practice for management of multiple myeloma.

Key Highlights

  • Lenalidomide maintenance following ASCT is established as the standard of care.
  • Continuous treatment for non-transplant eligible patients shows significant benefits.
  • Emerging therapies are being investigated for maintenance treatment.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of multiple myeloma should be confirmed through clinical and laboratory criteria.

Management

  • Maintenance therapy should be considered after induction and consolidation phases.

Monitoring & Follow-up

  • Regular assessment of progression-free survival (PFS) and overall survival (OS) is recommended.

Risks

  • Potential for disease progression and treatment-related toxicities should be evaluated.

Patient & Prescribing Data

Patients with newly diagnosed multiple myeloma, both transplant eligible and ineligible.

Lenalidomide is commonly used in maintenance therapy, with ongoing studies on novel therapies.

Clinical Best Practices

  • Utilize a systematic approach for maintenance therapy selection based on individual patient factors.
  • Incorporate emerging therapies into treatment plans as evidence supports their efficacy.

Related Resources & Content

Original Source(s)

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

  • by Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María-Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld

  • June 18, 2026

Related Content

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer

Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min